Theriva Biologics Inc (TOVX) Stock Price, Quote & News

Company Profile

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for trea...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 417 4364

Website: therivabio.com

Address:

9605 Medical Center Drive, Suite 270, Rockville, United States

pedro_333 Jun. 4 at 5:33 PM

$TOVX does anyone know the date of the next warrant meeting taking place? Best for all off you

2 · Reply

Lovelife68 Jun. 3 at 9:01 PM

$TOVX anybody else going to send in documentation like mark Nejmah did?

0 · Reply

StockBoySam Jun. 3 at 3:41 PM

$TOVX I am writing this post as a test to see if posted. Somehow, prior posts sent were only visible to me. Thank you.

1 · Reply

StockBoySam Jun. 3 at 3:14 PM

$TOVX New information from Newsweed on youtube today. It may have been posted yesterday. https://www.youtube.com/shorts/-tGgRMEjKWc?feature=share

0 · Reply

StockBoySam Jun. 3 at 2:11 PM

$TOVX A link from youtube https://i.ytimg.com/vi/-tGgRMEjKWc/oar2.jpg?sqp=-oaymwEoCJUDENAFSFqQAgHyq4qpAxcIARUAAIhC2AEB4gEKCBgQAhgGOAFAAQ==&rs=AOn4CLArVwCBj-T8kRI89DVaskYQ43inKQ&usqp=CCk

0 · Reply

StockBoySam Jun. 3 at 1:56 PM

$TOVX Did you happen to see Newsweed's latest video on youtube? demand for voting logs and data ledger Nevada rule 78.257 vote no

0 · Reply

StockBoySam Jun. 3 at 1:30 PM

$TOVX Some youtube information https://youtube.com/shorts/-tGgRMEjKWc?si=XRuuTh3Z3Z6riob2

0 · Reply

StockBoySam Jun. 3 at 1:28 PM

$TOVX https://youtube.com/shorts/-tGgRMEjKWc?si=XRuuTh3Z3Z6riob2

0 · Reply

StockBoySam Jun. 3 at 1:27 PM

$TOVX https://youtube.com/shorts/-tGgRMEjKWc?si=XRuuTh3Z3Z6riob2

0 · Reply

StockBoySam Jun. 3 at 1:25 PM

$TOVX https://youtube.com/shorts/-tGgRMEjKWc?si=XRuuTh3Z3Z6riob2

0 · Reply

Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results

May 5, 2026, 4:00 PM EDT - 4 weeks ago

Theriva Biologics Earnings release: Q1 2026

May 5, 2026, 4:00 PM EDT - 4 weeks ago

Theriva Biologics Quarterly report: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Theriva Biologics Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 6 weeks ago

Theriva Biologics Proxy statement: Proxy filing

2026-04-17T20:11:52.000Z - 6 weeks ago

Theriva Biologics to present additional data on Phase 2b VCN-01Clinical Trial

Apr 17, 2026, 4:05 PM EDT - 6 weeks ago

Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting

2026-03-31T13:48:40.000Z - 2 months ago

Theriva Biologics upgraded to Buy at Maxim on clearer VCN-01 path

2026-03-31T11:54:39.000Z - 2 months ago

Theriva Biologics upgraded to Buy from Hold at Maxim

2026-03-23T12:10:57.000Z - 2 months ago

Theriva Biologics announces outcome of Type B End-of-Phase 2 meeting with FDA

Mar 16, 2026, 8:00 AM EDT - 2 months ago

Theriva Biologics Proxy statement: Proxy Filing

2026-03-13T13:38:56.000Z - 2 months ago

Theriva Biologics price target lowered to $4 from $7 at Alliance Global

2026-03-12T12:07:24.000Z - 3 months ago

Theriva Biologics reports FY25 EPS ($2.08) vs. ($19.03) last year

2026-03-12T12:05:50.000Z - 3 months ago

Theriva Biologics sees cash runway into 1Q27

Mar 12, 2026, 7:00 AM EDT - 3 months ago

Theriva Biologics Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 3 months ago

Theriva Biologics Annual report: Q4 2025

Mar 4, 2026, 7:00 AM EST - 3 months ago

Theriva Biologics Proxy statement: Proxy Filing

2026-02-18T13:16:44.000Z - 3 months ago

Theriva Biologics licenses SYN-020 to Rasayana Therapeutics

Jan 5, 2026, 7:00 AM EST - 5 months ago

Theriva Biologics Proxy statement: Proxy Filing

2025-12-29T13:05:25.000Z - 5 months ago

Theriva Biologics receives CHMP scientific advice on VCN-01 Phase 3 design

Dec 29, 2025, 8:00 AM EST - 5 months ago

Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Dec 23, 2025, 7:00 AM EST - 5 months ago

Theriva Biologics Proxy statement: Proxy Filing

2025-11-12T13:16:18.000Z - 7 months ago

Theriva Biologics reports Q3 EPS (45c) vs ($6.81) last year

Nov 12, 2025, 8:00 AM EST - 7 months ago

Theriva Biologics Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 7 months ago

Theriva Biologics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 7 months ago

Theriva Biologics Proxy statement: Proxy Filing

Nov 10, 2025, 7:00 AM EST - 7 months ago

Theriva Biologics Proxy statement: Proxy Filing

2025-11-07T21:40:16.000Z - 7 months ago

Theriva Biologics files to sell 16.18M shares of common stock for holders

Nov 7, 2025, 7:00 AM EST - 7 months ago

Theriva Biologics Registration statement: Registration Filing

Oct 31, 2025, 8:00 AM EDT - 7 months ago

Theriva Biologics Proxy statement: Proxy Filing

2025-10-24T18:40:09.000Z - 7 months ago

Theriva Biologics sees no material development to account for unusual trading

Oct 24, 2025, 2:31 PM EDT - 7 months ago

Theriva Biologics Provides Response to Unusual Market Action

2025-10-16T12:20:41.000Z - 8 months ago

Theriva Biologics announces warrant inducement transaction for $4M in proceeds

Oct 16, 2025, 8:11 AM EDT - 8 months ago

Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds

Oct 6, 2025, 8:00 AM EDT - 8 months ago

Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

2025-08-11T12:12:44.000Z - 10 months ago

Theriva Biologics reports Q2 EPS ($1.93) vs. ($10.72) last year

2025-08-11T12:12:22.000Z - 10 months ago

Theriva Biologics sees cash runway into 1Q26

Aug 11, 2025, 8:00 AM EDT - 10 months ago

Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results

Aug 11, 2025, 8:00 AM EDT - 10 months ago

Theriva Biologics Quarterly report: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 10 months ago

Theriva Biologics Earnings release: Q2 2025

Jul 9, 2025, 8:00 AM EDT - 11 months ago

Theriva Biologics Proxy statement: Proxy Filing

2025-05-27T12:20:41.000Z - 1 year ago

Theriva Biologics announces presentation of data from VCN-01 Phase 1 trial

2025-05-14T12:52:55.000Z - 1 year ago

Theriva Biologics reports Q1 EPS ($1.55) vs ($7.53) last year

2025-05-14T12:52:08.000Z - 1 year ago

Theriva Biologics sees cash runway into 1Q26

May 14, 2025, 8:40 AM EDT - 1 year ago

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

May 14, 2025, 8:00 AM EDT - 1 year ago

Theriva Biologics Quarterly report: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

Theriva Biologics Earnings release: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Theriva Biologics Announces Closing of $7.5 Million Public Offering

2025-05-08T12:43:45.000Z - 1 year ago

Theriva Biologics downgraded to Hold from Buy at Maxim

May 7, 2025, 9:17 AM EDT - 1 year ago

Theriva Biologics Announces Pricing of $7.5 Million Public Offering

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Mar 21, 2025, 8:00 AM EDT - 1 year ago

Theriva Biologics Registration statement: Registration Filing

Mar 19, 2025, 8:10 AM EDT - 1 year ago

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

Mar 6, 2025, 4:10 PM EST - 1 year ago

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

Mar 6, 2025, 8:30 AM EST - 1 year ago

Theriva Biologics Earnings release: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Theriva Biologics Annual report: Q4 2024

Mar 5, 2025, 4:05 PM EST - 1 year ago

Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual

Jan 21, 2025, 7:00 AM EST - 1 year ago

Theriva Biologics Registration statement: Registration Filing

Dec 10, 2024, 7:00 AM EST - 1 year ago

Theriva Biologics Registration statement: Registration Filing

Dec 5, 2024, 8:00 AM EST - 1 year ago

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Nov 12, 2024, 7:00 AM EST - 1 year ago

Theriva Biologics Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Theriva Biologics Earnings release: Q3 2024

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Theriva Biologics Proxy statement: Proxy Filing

Sep 26, 2024, 9:06 PM EDT - 1 year ago

Theriva Biologics Announces Pricing of $2.5 Million Public Offering

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Theriva Biologics Registration statement: Registration Filing

Sep 18, 2024, 8:00 AM EDT - 1 year ago

Theriva Biologics Proxy statement: Proxy Filing

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program

Sep 11, 2024, 8:00 AM EDT - 1 year ago

Theriva Biologics Registration statement: Registration Filing

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Theriva Biologics Registration statement: Registration Filing

Aug 16, 2024, 4:05 PM EDT - 1 year ago

Theriva Biologics Announces Reverse Stock Split

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Theriva Biologics Quarterly report: Q2 2024

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Theriva Biologics Earnings release: Q2 2024

Jul 31, 2024, 8:15 AM EDT - 2 years ago

Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma

May 23, 2024, 8:15 AM EDT - 2 years ago

Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

May 14, 2024, 8:00 AM EDT - 2 years ago

Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference

May 7, 2024, 7:00 AM EDT - 2 years ago

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results

May 7, 2024, 7:00 AM EDT - 2 years ago

Theriva Biologics Quarterly report: Q1 2024

May 7, 2024, 7:00 AM EDT - 2 years ago

Theriva Biologics Earnings release: Q1 2024

May 2, 2024, 8:00 AM EDT - 2 years ago

Theriva Biologics Registration statement: Registration Filing

Apr 25, 2024, 8:15 AM EDT - 2 years ago

Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annua

$Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma$

Apr 23, 2024, 7:00 AM EDT - 2 years ago

Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma

Apr 22, 2024, 4:35 PM EDT - 2 years ago

Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting

Apr 8, 2024, 8:00 AM EDT - 2 years ago

Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting

Mar 25, 2024, 8:30 AM EDT - 2 years ago

Theriva Biologics Earnings Call Transcript: Q4 2023

Mar 25, 2024, 8:30 AM EDT - 2 years ago

Theriva Biologics Annual report: Q4 2023

Mar 25, 2024, 8:30 AM EDT - 2 years ago

Theriva Biologics Earnings release: Q4 2023

Mar 25, 2024, 7:30 AM EDT - 2 years ago

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results

Mar 11, 2024, 8:00 AM EDT - 2 years ago

Theriva™ Biologics to Participate in the BIO-Europe Spring Conference

Feb 7, 2024, 8:00 AM EST - 2 years ago

Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

Jan 16, 2024, 8:00 AM EST - 2 years ago

Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference

Nov 13, 2023, 8:30 AM EST - 2 years ago

Theriva Biologics Earnings Call Transcript: Q3 2023

Nov 13, 2023, 8:30 AM EST - 2 years ago

Theriva Biologics Quarterly report: Q3 2023

Nov 13, 2023, 8:00 AM EST - 2 years ago

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

Nov 6, 2023, 4:05 PM EST - 2 years ago

Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial Results

Nov 2, 2023, 4:15 PM EDT - 2 years ago

Theriva™ Biologics to Participate in the BIO-Europe Conference

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Theriva™ Biologics and Sant Joan de Déu-Barcelona Children's Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Theriva™ Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Sep 28, 2023, 8:00 AM EDT - 2 years ago

Theriva Biologics to Participate in the Emerging Growth Conference

Aug 16, 2023, 8:00 AM EDT - 3 years ago

Theriva Biologics Proxy statement: Proxy Filing

Aug 14, 2023, 8:00 AM EDT - 3 years ago

Theriva Biologics Proxy statement: Proxy Filing

Aug 8, 2023, 8:30 AM EDT - 3 years ago

Theriva Biologics Earnings Call Transcript: Q2 2023

Aug 8, 2023, 8:30 AM EDT - 3 years ago

Theriva Biologics Quarterly report: Q2 2023

Aug 8, 2023, 8:00 AM EDT - 3 years ago

Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results

Aug 2, 2023, 7:00 AM EDT - 3 years ago

Theriva™ Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

Aug 1, 2023, 4:05 PM EDT - 3 years ago

Theriva Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2023 Operational Highlights and Financial Results

Jun 27, 2023, 4:10 PM EDT - 3 years ago

Theriva Biologics Announces Orphan Drug Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Pancreatic Cancer

May 23, 2023, 8:00 AM EDT - 3 years ago

Theriva Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of Discovery

May 11, 2023, 8:30 AM EDT - 3 years ago

Theriva Biologics Earnings Call Transcript: Q1 2023

May 11, 2023, 8:30 AM EDT - 3 years ago

Theriva Biologics Quarterly report: Q1 2023

May 11, 2023, 8:00 AM EDT - 3 years ago

Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results

May 4, 2023, 8:00 AM EDT - 3 years ago

Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results

Apr 13, 2023, 8:00 AM EDT - 3 years ago

Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Mar 30, 2023, 8:30 AM EDT - 3 years ago

Theriva Biologics Earnings Call Transcript: Q4 2022

Mar 30, 2023, 8:30 AM EDT - 3 years ago

Theriva Biologics Earnings release: Q4 2022

Mar 30, 2023, 8:30 AM EDT - 3 years ago

Theriva Biologics Annual report: Q4 2022

Mar 30, 2023, 8:00 AM EDT - 3 years ago

Theriva Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

Mar 24, 2023, 4:05 PM EDT - 3 years ago

Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

pedro_333 Jun. 4 at 5:33 PM

$TOVX does anyone know the date of the next warrant meeting taking place? Best for all off you

2 · Reply

Lovelife68 Jun. 3 at 9:01 PM

$TOVX anybody else going to send in documentation like mark Nejmah did?

0 · Reply

StockBoySam Jun. 3 at 3:41 PM

$TOVX I am writing this post as a test to see if posted. Somehow, prior posts sent were only visible to me. Thank you.

1 · Reply

StockBoySam Jun. 3 at 3:14 PM

$TOVX New information from Newsweed on youtube today. It may have been posted yesterday. https://www.youtube.com/shorts/-tGgRMEjKWc?feature=share

0 · Reply

StockBoySam Jun. 3 at 2:11 PM

$TOVX A link from youtube https://i.ytimg.com/vi/-tGgRMEjKWc/oar2.jpg?sqp=-oaymwEoCJUDENAFSFqQAgHyq4qpAxcIARUAAIhC2AEB4gEKCBgQAhgGOAFAAQ==&rs=AOn4CLArVwCBj-T8kRI89DVaskYQ43inKQ&usqp=CCk

0 · Reply

StockBoySam Jun. 3 at 1:56 PM

$TOVX Did you happen to see Newsweed's latest video on youtube? demand for voting logs and data ledger Nevada rule 78.257 vote no

0 · Reply

StockBoySam Jun. 3 at 1:30 PM

$TOVX Some youtube information https://youtube.com/shorts/-tGgRMEjKWc?si=XRuuTh3Z3Z6riob2

0 · Reply

StockBoySam Jun. 3 at 1:28 PM

$TOVX https://youtube.com/shorts/-tGgRMEjKWc?si=XRuuTh3Z3Z6riob2

0 · Reply

StockBoySam Jun. 3 at 1:27 PM

$TOVX https://youtube.com/shorts/-tGgRMEjKWc?si=XRuuTh3Z3Z6riob2

0 · Reply

StockBoySam Jun. 3 at 1:25 PM

$TOVX https://youtube.com/shorts/-tGgRMEjKWc?si=XRuuTh3Z3Z6riob2

0 · Reply

StockBoySam Jun. 3 at 1:23 PM

$TOVX https://youtube.com/shorts/-tGgRMEjKWc?si=XRuuTh3Z3Z6riob2 Let's see if this posts from youtube.

0 · Reply

WallStreetLiving Jun. 2 at 7:55 PM

$TOVX anyone saying to vote no is 100% shorting this stock. Thats stock suicide. Vote PASSES = $8.7M cash comes in immediately, Going-concern language removed from financials, Dilution of ~35% but offset by balance sheet strength, new buyer categories unlocked — funds that can't hold going-concern stocks suddenly eligible, Borrow rate likely spikes as shorts scramble ,Stock targets $0.54+ immediately as warrant exercise price becomes the floor, Potential move: 50-100%+ from current levels

1 · Reply

partylike1989 Jun. 2 at 5:16 PM

$TOVX Paying 40% in interest fees WOW GET READY WHEN ITS UNEXPECTED THIS GOIBG TO BLOW UP. ⬆️ keep buying

2 · Reply

OhHappyDays Jun. 2 at 2:22 PM

$TOVX Sorry everyone. I sold all my shares on this one. That drop on SLS was too tempting and I gave in. I wish y'all the best with this one. I still voted NO for y'all but I have to go with what's actually moving and this one hasn't given nothing. Best of luck to all that hold.

1 · Reply

Flazz72 Jun. 2 at 2:19 PM

$TOVX Do not let dilution of your shares take place. VOTE NO!

0 · Reply

EGYXee Jun. 1 at 9:09 PM

$TOVX If this is going to run, it has to touch the 0.24$-0.25$ limts to close the gap first.

1 · Reply

Kri81 May. 29 at 6:34 PM

$TOVX Why, but why? Why are you selling?

0 · Reply

Tradelyfe May. 29 at 6:03 PM

$TOVX is this POS going back to .18?

1 · Reply

Kri81 May. 29 at 5:38 PM

$TOVX Hey. Its just positive . Lets jump

0 · Reply

Godfather12U May. 29 at 3:56 PM

$TOVX Jumped in again Good price

0 · Reply

StockBoySam May. 29 at 3:18 PM

$TOVX Let's see if this finally posts. https://www.youtube.com/watch?v=wfzN0FiC0dk

0 · Reply

StockBoySam May. 29 at 3:10 PM

$TOVX I am once again voting against dilution with a strong NO vote!

1 · Reply

Market Cap	9.65M
Revenue (ttm)	0.00
Net Income (ttm)	-23.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.11

Volume	887,600
Avg Vol	20,088,156
Day's Range	N/A - N/A
Shares Out	33.74M
Stochastic %K	20%
Beta	1.10
Analysts	Strong Sell
Price Target	$2.50